麻豆传媒

Meeting Coverage >

EASL

'A New Hope' for Rare, Deadly Liver Disease

Small fazirsiran trial sees fibrosis regressions for liver disease associated with AAT deficiency

Mixed Bag for Semaglutide in NASH-Related Compensated Cirrhosis

Randomized trial showed improvements in cardiometabolic markers, but not liver fibrosis

Liver Cirrhosis Tied to Elevated Risk for Stroke

37% higher risk observed in large German study

Bulevirtide's Effect Sustained in Difficult-to-Treat Hepatitis D

Nearly half of patients at week 48 had virological and biochemical response

German Study Warns of Increasing Acute Hep C Reinfections in MSM

14% of patients experienced a reinfection over the past decade

Early Liver Disease Detection Linked to Subsequent Lifestyle Improvements

Danish study shows fibrosis screening associated with improved diet, alcohol use, and exercise

Novel Liver Assist Device Safe for Patients With Cirrhosis

Small preliminary trial also shows hints of promising clinical results

Resmetirom Delivers Promising Outcomes in NASH Without Invasive Follow-Up

Real-world study also identifies noninvasive markers for treatment response

Food Insecurity Tied to More Liver Disease Deaths

Social determinants of health play a key role, study found

Dads With Obesity Mostly Cleared in Their Children's NAFLD

U.K. study confirms it's mainly mom's fault

Adding PD-1 Inhibitor Shows Promise in Potentially Resectable HCC

"Safe and successful conversion therapy" with hepatic arterial infusion chemo plus sintilimab

Tenofovir Treatment Lessened Risk of Severe COVID Infection in HBV

But expert questions conclusion of small study from Spain

Bulevirtide Shows Promise in Tough-to-Treat Hepatitis D

Significant responses seen with novel agent for "devil" disease

Big Jump in Monthly Average Hospital Admission for Alcoholic Hepatitis Post-Pandemic

Long-term impact of alcohol uptake on liver health during COVID-19 crisis remains unknown

Liver Fibrosis Linked to Lower Response to COVID Vaccine

Third dose may be needed in this population as well as some transplant patients, says researcher

The Murky Post-Pandemic Future of Hepatitis C Elimination in the U.S.

Modeling study demonstrates need to rebound or risk losing progress

Rise in Alcohol Dependence Seen During Pandemic

AUD in U.K. study tied to worse COVID outcomes and more mental health problems as well

Liver Disease Tied to Increased Risk of Death From Severe COVID

French study of hospitalized patients also saw an increased risk of mechanical ventilation

Core Protein Inhibitor: A Key to Eventual HBV Cure?

Entecavir plus novel core protein inhibitor led to dramatic declines in hepatitis B DNA, RNA

Promising Results with Givosiran in Acute Hepatic Porphyrias

Patients on novel agent showed significant urinary ALA reduction versus placebo

Combo Tx With 'Entry Inhibitor' Latest Hope in Treating Hep D

Myrcludex B and interferon shows promise in HBV/HDV co-infection

Drug Shows Promise in Treating NASH

Obeticholic acid improves fibrosis in interim phase III data

Cirrhosis 'Turning Point' in Fatty Liver Progression

Most patients identified with decompensated event, real-world study finds

Cure for Hepatitis B Pushed

Disease affecting 257 million people needs better treatment

Novel Non-Bile FXR Agonist Promising in PBC Patients

Phase II trial interim analysis found dose-dependent response, good safety profile

Biliary Fibrosis Stabilized with Obeticholic Acid

Biopsy study supports anti-fibrosis properties of agent

Hepatitis C Treatments Reduce Transplants

Therapies also appear to reduce liver-related mortality

Europe Gets Updated HCV Tx Guidelines

EASL panel touts 'ease of use' of direct-acting antivirals

SIRT + Sorafenib = No Survival Bump in Liver Cancer

But clinical benefits suggested in certain patients with less severe disease

Lipid-Lowering Drug Offers New Hope in PBC

First gold standard trial confirms benefits of bezafibrate

Climate Tied to Alcohol-Related Liver Disease

Is alcoholic cirrhosis a product of cold, gray weather?

Liver Cancer Tx with Radioactive Beads Yields Mixed Results

No survival benefit but quality of life better

Gum Disease, Mortality Linked in Cirrhosis

Severity of periodontitis increases risk

Simple, Short HCV Regimen Has High Cure Rate

LONDON -- A single pill once a day for 8 weeks is enough to cure more than 90% of hepatitis C virus patients with relatively uncomplicated disease, a researcher said.

Fatty Liver Tied to Diabetes, Atherosclerosis

LONDON -- Non-alcoholic fatty liver disease (NAFLD) is an independent predictor of both type 2 diabetes and carotid atherosclerosis, according to two studies presented here at the annual meeting of the European Association for the Study of the Liver.